Effects of novel 17α-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo

Journal of Steroid Biochemistry and Molecular Biology

Volumn 84, Issue 5, 2003, Pages 555-562

  Haidar, Samer ^a   Ehmer, Peter B ^a   Barassin, Stephan ^b   Batzl Hartmann, Christine ^b   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Pharmacelsus CRO   (Germany)

Author keywords

17 Hydroxylase C17; 20 Lyase (CYP 17); 5 Reductase; Androgen biosynthesis; CYP 17 (P450 17) inhibitors; Prostate cancer

Indexed keywords

17 (5 PYRIMIDYL)ANDROSTA 5,16 DIEN 3BETA OL; 3,4 DIHYDRO 2 (4 IMIDAZOLYLMETHYL) 6 METHOXY 1 METHYLNAPHTHALENE; ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN; BW 19; CB 7630; CYTOCHROME P450C17; ENZYME INHIBITOR; KETOCONAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SA 40; SA 41; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; CYTOCHROME P450; ISOENZYME; NAPHTHALENE DERIVATIVE; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE;

ADRENAL GLAND; ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; HYPOPHYSIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LEVATOR ANI MUSCLE; MALE; MICROSOME; NONHUMAN; ORGAN WEIGHT; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; SEMINAL VESICLE; TESTIS; TESTOSTERONE BLOOD LEVEL; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; ORGAN SIZE; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ESCHERICHIA COLI;

ANDROGENS; ANDROSTENOLS; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; KETOCONAZOLE; MALE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NAPHTHALENES; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SEMINAL VESICLES; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; TESTIS; TESTOSTERONE;

EID: 0038062686     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00070-0     Document Type: Article

References (32)

1. Nnane I.P., Long B.J., Ling Y.-Z., Grigoryev D.N., Brodie A.M. Anti-tumour effects and pharmacokinetic profile of 17-(5-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. Br. J. Cancer. 83:2000;74-82.
2. Jarman M., Smith J.H., Nicholls P.J., Simons C. Inhibitors of enzymes of androgen biosynthesis: cytochrome P450 17α and 5α steroid-reductase. Nat. Prod. Rep. 24:1998;495-512.
3. Hartmann R.W., Ehmer P.B., Haidar S., Hector M., Jose J., Klein C.D.P., Seidel S., Sergejew T.F., Wachall B.G., Wächter G.A., Zhuang Y. Inhibition of CYP 17: a new strategy for the treatment of prostate cancer. Arch. Pharm. Pharm. Med. Chem. 335:2002;119-128. and references cited therein.
4. Long B.J., Grigoryev D.N., Nnane I.P., Liu Y., Ling Y.-Z., Brodie A.M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res. 60:2000;6630-6640.
5. Schuurmans A.L., Bolt J., Veldscholte J., Mulder E. Stimulatory effects of antiandrogens on LNCaP human prostate tumour cell growth, EGF-receptor level and acid phosphatase secretion. J. Steroid Biochem. Mol. Biol. 37:1990;849-853.
6. De Coster R., Wouters W., Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J. Steroid Biochem. Mol. Biol. 56:1996;133-143.
7. Nakajin S., Shively J.E., Yuan P.M., Hall P.F. Microsomomal cytochrome P450 from neonatal pig testis: two enzymatic activities (17α-hydroxylase and C17, 20-lyase) associated with one protein. Biochemistry. 20:1981;4037-4042.
8. Higashi Y., Omura M., Suzuki K., Inano H., Oshima H. Ketoconazole as a possible universal inhibitor of cytochrome P450 dependent enzymes: its mode of inhibition. Endocrinol. Japon. 34:1987;105-115.
9. Ayub M., Levell M. Inhibition of testicular 17alpha-hydroxylase and C17, 20-lyase but not 3beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J. Steroid Biochem. 28:1987;521-531.
10. Trachtenberg J., Halpern N., Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J. Urol. 132:1984;61-63.
11. Njar V.C.O., Brodie A.M.H. Inhibitors of 17α-hydroxylase/C17, 20-lyase (CYP17): potential agents for the treatment of prostate cancer. Curr. Pharm. Des. 5:1999;163-180.
12. Hartmann R.W., Hector M., Haidar S., Ehmer P.B., Reichert W., Jose J. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17α-hydroxlase/C17-20-lyase) and 5α-reductase types 1 and 2. J. Med. Chem. 43:2000;4266-4277. and references cited therein.
13. Hartmann R.W., Hector M., Wachall B.G., Palusczak A., Palzer M., Huch V., Veith M. Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17α-hydroxlase/C17-20-lyase (P450 17). J. Med. Chem. 43:2000;4437-4445.
14. Potter G.A., Barrie E.S., Jarman M., Rowlands M.G. Novel steroidal inhibitors of human cytochrome P450 17α: potential agents for the treatment of prostatic cancer. J. Med. Chem. 38:1995;2463-2471.
15. Ideyama Y., Kudoh M., Tanimoto K., Susaki Y., Nanya T., Nakahara T., Ishikawa H., Yoden T., Okada M., Fujikura T., Akaza H., Shikama H. Novel non-steroidal inhibitor of cytochrome P450 17 (17α-hydroxylase-C17-20-lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Prostate. 37:1998;10-18.
16. Ideyama Y., Kudoh M., Tanimoto K., Susaki Y., Nanya T., Nakahara T., Ishikawa H., Fujikura T., Akaza H., Shikama H. YM116, 2-(1H-imidazole-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20-lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jap. J. Pharmacol. 79:1999;213-220.
17. Wachall B.W., Hector M., Zhuang Y., Hartmann R.W. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer. Bioorg. Med. Chem. 7:1999;1913-1924.
18. Zhuang Y., Wachall B.W., Hartmann R.W. Novel imidazolyl and triazolyl biphenyl compounds: synthesis and evaluation as non-steroidal inhibitors of human 17α-hydroxylase-C17, 20-lyase (P450 17). Bioorg. Med. Chem. 8:2000;1245-1252.
19. Rowlands M.G., Barrie S.E., Chan F., Jarman M., McCague R., Potter G.A. Esters of 3-pyridylacetic acid that combine potent inhibition of 17α-hydroxylase/C17-20-lyase with resistance to esterase hydrolysis. J. Med. Chem. 38:1995;4191-4197.
20. Chan F.C.Y., Potter G.A., Barrie S.E., Haynes B.P., Rowlands M.G., Houghton J., Jarman M. 3- and 4-pyridylalkyl adamantanecarboxylates: inhibition of human cytochrome P450 17α (17α-hydroxylase/C17, 20-lyase), potential non-steroidal agents for the treatment of prostatic cancer. J. Med. Chem. 39:1996;3319-3323.
21. BTG International Ltd., http://www.btgplc.com, Abiraterone Acetate: A New Treatment for Prostate Cancer.
22. R.W. Hartmann, B. Wachall, M. Yoshihama, M. Nakakoshi, S. Nomoto, Y. Ikeda, Novel Dihydronaphthalene Compounds and Processes of Producing the Same, US Patent US 2002/0032211 A1.
23. Haidar S., Ehmer P.B., Hartmann R.W. Novel steroidal pyrimidyl inhibitors of P450 17 (17α-hydroxylase/C17-20-lyase). Arch. Pharm. Pharm. Med. Chem. 334:2001;373-374.
24. Sergejew T., Hartmann R.W. Pyridyl substituted benzocycloalkenes: new inhibitors of 17α-hydroxylase/C17-20-lyase (P450-17α). J. Enzyme Inhib. 8:1994;113-122.
25. m. Biochim. Biophys. Acta. 242:1971;519-522.
26. Ehmer P.B., Jose J., Hartmann R.W. Development of a simple and rapid assay for the evaluation of inhibitors of human 17α-hydroxylase-C17, 20-lyase (P450c17) by coexpression of P450c17 with NADPH-cytochrome-P450-reductase in Escherichia coli. J. Steroid Biochem. Mol. Biol. 75:2000;57-63.
27. Njar V.C.O., Hector M., Hartmann R.W. 20-Amino and 20,21-aziridinyl pregnene steroids: development of potent inhibitors of 17α-hydroxylase/17, 20-lyase (P450 17). Bioorg. Med. Chem. 4:1996;1447-1453.
28. Ehmer P.B., Bureik M., Bernhardt R., Müller U., Hartmann R.W. Development of a test system for inhibitors of human aldosterone synthase (CYP 11B2): screening in fission yeast and evaluation of selectivity in V 79 cells. J. Steroid Biochem. Mol. Biol. 81:2002;173-179.
29. Hartmann R.W., Batzl C. Aromatase inhibitors synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J. Med. Chem. 29:1986;1362-1369.
30. Jarman M., Barrie S.E., Llera J.M. The 16, 17-double bond is needed for irreversible inhibition of human cytochrome P450 17α by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3β-ol) and related steroidal inhibitors. J. Med. Chem. 41:1998;5375-5381.
31. Barrie S.E., Potter G.A., Goddard P.M., Haynes B.P., Dowsett M., Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450 17α (17α-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 50:1994;267-273.
32. Häusler A., Allegrini P.R., Biollaz M., Batzl Ch., Scheidegger E., Bhatnagar A.S. CGP 53153: a new potent inhibitor of 5α-reductase. J. Steroid Biochem. Mol. Biol. 57:1996;187-195.